LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Home・Akciju saraksts・Myriad Genetics Inc

Myriad Genetics Inc

Slēgts

SektorsVeselības aprūpe

6.28 -1.1

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

6.08

Max

6.36

Galvenie mērījumi
By Trading Economics
Ienākumi	-330M -331M
Pārdošana	17M 213M
Peļņas marža	-155.092
Darbinieki	2,700
EBITDA	-301M -315M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+29.54% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	394M 761M
Iepriekšējā atvēršanas cena	7.38
Iepriekšējā slēgšanas cena	6.28

Ziņu noskaņojums

By Acuity

50%

183 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

N/A / 7.55 Atbalsts un pretestība

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 7. nov. 21:06 UTC

Galvenie tirgus virzītāji

JBS Down After Trump Calls for Probe into Meat-Packing Companies

2025. g. 7. nov. 22:36 UTC

Peļņas

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

2025. g. 7. nov. 22:22 UTC

Peļņas

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

2025. g. 7. nov. 22:03 UTC

Peļņas

Constellation Software 3Q Rev $2.95B >CSU.T

2025. g. 7. nov. 22:03 UTC

Peļņas

Constellation Software 3Q Net $210M >CSU.T

2025. g. 7. nov. 22:03 UTC

Peļņas

Constellation Software 3Q EPS $9.89 >CSU.T

2025. g. 7. nov. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 7. nov. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 7. nov. 20:59 UTC

Peļņas

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

2025. g. 7. nov. 20:26 UTC

Tirgus saruna

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

2025. g. 7. nov. 20:22 UTC

Peļņas

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

2025. g. 7. nov. 20:04 UTC

Tirgus saruna

Oil Futures Close Choppy Week With Losses -- Market Talk

2025. g. 7. nov. 19:34 UTC

Tirgus saruna

Gold Posts Small Gain for Week -- Market Talk

2025. g. 7. nov. 19:31 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

2025. g. 7. nov. 19:17 UTC

Peļņas

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

2025. g. 7. nov. 19:09 UTC

Peļņas

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

2025. g. 7. nov. 19:08 UTC

Peļņas

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

2025. g. 7. nov. 18:31 UTC

Tirgus saruna

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

2025. g. 7. nov. 17:27 UTC

Tirgus saruna

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

2025. g. 7. nov. 17:20 UTC

Tirgus saruna

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

2025. g. 7. nov. 17:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 7. nov. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 7. nov. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 7. nov. 17:17 UTC

Iegādes, apvienošanās, pārņemšana

Satair Expects to Complete Purchase in Early 2026

2025. g. 7. nov. 17:17 UTC

Iegādes, apvienošanās, pārņemšana

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

2025. g. 7. nov. 17:15 UTC

Iegādes, apvienošanās, pārņemšana

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

2025. g. 7. nov. 17:09 UTC

Tirgus saruna

PENN Is Falling Further Behind Competitors -- Market Talk

2025. g. 7. nov. 16:49 UTC

Tirgus saruna

Losing ESPN Partnership Will Hurt PENN -- Market Talk

2025. g. 7. nov. 16:24 UTC

Tirgus saruna

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

2025. g. 7. nov. 16:17 UTC

Tirgus saruna

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

29.54% augšup

Prognoze 12 mēnešiem

Vidējais 8.2 USD 29.54%

Augstākais 9 USD

Zemākais 7 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

N/A / 7.55Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

All events are bearish.

Noskaņojums

By Acuity

183 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.